SANTA MONICA, CA / ACCESSWIRE / April 28, 2016 / Today, Esse Nutrition, LLC announced their launch of VITAGURL, a new brand of women’s beauty & lifestyle supplements. The boutique vitamin line designed by women, for women focuses on being ageless, with a variety of premium quality supplements targeted to the Gen X woman.

While the VMS industry is huge and growing in the U.S., there has been little focus on approaching the category from an anti-aging beauty angle, specifically targeting optimum health for women.

As noted in recent Datamonitor research, China and Japan are setting the trend for using women’s supplements for beauty from the inside out, and are leading this segment’s market growth.

With social media and lifestyle health & wellness becoming more and more important for the younger generation, Vitagurl is coming at the right time.

“Women from our generation are interested in living longer and healthier,” says Kristin Chadwick, founder of Vitagurl. “We know that if you feel good, you look good. We want to spread the word about optimum health not only through our supplements, but through fun, exciting inspiration that supports a positive outlook on life.”

Vitagurl plans to launch online, through social channels at facebook.com/vitagurl and instagram.com/vitagurl, influencers and women’s events. To learn more, visit us here or contact support@vitagurl.com.

About Vitagurl:

VITAGURL is a new, premium line of beauty supplements that are designed for women, by women. The “Be Ageless” line consist of soy-free, gluten-free and non-gmo formulas that focus on optimum health including supporting memory, digestion, sleep, mood, weight management and beauty. The VITAGURLS, based out of Santa Monica, CA promote messages of health, fitness, beauty and all things positive.

SOURCE: Vitagurl

ReleaseID: 439315

As a Child, Vidali Suffered Terrible Burns from an Exploding Bottle of Gasoline

LOS ANGELES, CA / ACCESSWIRE / April 28, 2016 / Giulio Vidali is pleased to announce that he is scheduling a life changing overseas surgery. Vidali will soon travel from his home in Malaysia to the United States so he can undergo an intricate face transplant surgery.

As Vidali explained, when he was only 4 years old, a bottle of gasoline exploded and showered his small face and body with fire. He was burned on over 60 percent of his body, and suffered a great deal of damage to his face.

Over the years, Vidali traveled between Italy and the United States for a total of 48 reconstructive surgeries. Although his childhood and the multiple surgeries were difficult, Vidali said he always tried to be strong.

Now 31 and living in Malaysia with his wife Veronica and their two children Samantha and Christian, Vidali said he is ready to take another step to give him back a face that is free from scars and burns.

“Every time I go with my kids to a party I see other people staring at me, wondering what happened,” he said.

“And now my daughter is big enough to understand and I would like to avoid her friends asking what happened to her daddy. So I think it’s time for a change.”

After consulting with his longtime surgeon Dr. Jan Jackson, Vidali was delighted to learn that there are many new methods to help burn victims like him–including a face transplant surgery.

In order to raise enough money to pay for the costs associated with the innovative surgery, Vidali has launched a fundraiser on Indiegogo. He hopes to use crowdfunding to raise $5,000 to help Dr. Jackson fix his burned face.

To learn more about Vidali and his upcoming facial surgery and trip to America, and/or to make a donation to his fundraiser, please visit https://goo.gl/uHhLov.

About Giulio Vidali:

Giulio Vidali is an inspiring man who’s looking to come to America to receive a face transplant surgery. His reason for that is at four years old, he was close to the fireplace, and a bottle of gasoline exploded and burned over 60 percent of his body. He moved to Malaysia to find a new life, and now has two wonderful kids. His daughter who is six is named Samantha, and his son who is three is named Christian, and the mother of his children is an amazing woman named Veronica. He hopes to raise enough funds to move the U.S. and undergo Face Transplant surgery so he will have a second chance for a normal life with his family. People can find his project on Indiegogo, and support and contribute to the big change he’s looking to make.

Contact:

Myrtle Hayes
admin@rocketfactor.com
(949) 555-2861

SOURCE: Giulio Vidali

ReleaseID: 439330

NEW YORK, NY / ACCESSWIRE / April 28, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MWOG, PPCH, FDBL and SUNEQ are on high volume watch, particularly MWOG. Continue reading to find out why these stocks are getting so much interest today. – If you want reports on the day’s hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.

Midwest Oil and Gas Inc. (OTC: MWOG) Is an exploration stage company that engages in the exploration, development, and production of onshore oil and natural gas reserves.

When we first reported you on MWOG, shares were trading higher yesterday by over 1200% and ended up closing the day up over 600% on the day.

The stock brought in a lot of volume yesterday and it didn’t go unnoticed. We expect to see MWOG to continue to get a boost from the extra attention today, however, at a much more subdued and steady pace…

Subscribe Free To Receive Alerts Like These Sent To Your Inbox Get Your Free Membership Now.

Ascent Solar Technologies, Inc. (OTCQB: PPCH) Is a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic and colorectal cancer in Australia.

When we first alerted you on PPCH, shares had been on a steady rise ever since announcing last week that it had filed two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer.

However, yesterday, the stock gave back some of its recent gains, dropping about 9%. This was somewhat expected as it had hit overbought levels the day before, with an RSI (relative strength index) of 71.

Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.

Friendable, Inc. (OTC: FDBL) The company develops and disseminates a proximity based mobile-social media application that facilitates connections between people.

FDBL recently announced that their app has now achieved over 1 Million total downloads and over the past two trading days, the stock has exploded up almost 200% off massive volume.

If FDBL can continue to earn the amount of volume that it has been receiving, we believe it will continue to make these kinds of jaw dropping gains.

However, with an overbought RSI indicator of over 95, it might be time for this one to pull back a bit.

Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.

SunEdison, Inc. (OTC: SUNEQ) Is a renewable energy development company, develops, finances, installs, owns, and operates renewable power plants to residential, commercial, government, and utility customers.

Shares of SUNEQ (originally SUNE) have been in a world of hurt in 2016 and it only got worse when the company announced that it had filed for bankruptcy.

We have been following SUNEQ for quite a while now and believe that the stock isn’t going to perform until the company fixes both its financial and managerial issues.

NASDAQ Stock Alerts: Check Them Out Here To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.

About otc-expert.com

The OTC Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.

To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word “OTCLEADER”.

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The OTC Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The OTC Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit otc-expert.com/disclaimer website for a more detailed discussion of risks and disclosures.

Contact:

Justin Skibinski
The OTC Expert
info@otc-expert.com

SOURCE: The OTC Expert

ReleaseID: 439332

VANCOUVER, BC / ACCESSWIRE / April 28, 2016 / Cornerstone Metals Inc. (TSXV: CCC) (“Cornerstone” or the “Company”) is pleased to announce that it has signed a non-binding Letter of Intent (“LOI”) with private interests (“Owners”) outlining the terms of a transaction. The Transaction is proposed to be implemented through an Option Agreement, pursuant to which the Owners will grant to CCC an option to acquire from them a 100% undivided interest in and to the Topley Property (“Topley”), subject to a 3% NSR. The LOI is subject to due diligence, which the Company will commence immediately, while it proceeds to finalize a definitive option agreement to be executed upon completion of successful due diligence.

The Topley Property, located 60 kilometres east-southeast of Smithers, B.C., is a precious and base metal mineral prospect known as Topley-Richfield (Au-Ag-Pb-Zn-Cu) with significant underground development from 2 levels completed from 1927 to 1929 and significant more recent evaluations occurring from 1979 to 2007 including over 8,000m of drilling. Mineralization is structurally controlled and occurs in two quartz-carbonate alteration zones.

Pursuant to the terms of the LOI, the Option will be exercisable upon CCC paying to the Owners an aggregate of $200,000 cash and issuing an aggregate of 1,100,000 common shares of CCC according to the following tabled schedule:

Additionally, commencing on the sixth anniversary date, and every subsequent anniversary date, CCC will pay to the Owners $20,000 cash per year as an advanced NSR payment until commercial production begins on the Topley Property. The 3% NSR may be purchased from the Owners for $1 million per each 1% NSR. The advanced NSR payments will be credited towards an NSR buyout. On commercial production, bonus CCC shares of 500,000 would be issued to the Owners.

The execution of the Option Agreement will be subject to standard closing conditions for transactions of this nature, including but not limited to board and regulatory approvals.

About Cornerstone Metals Inc.

Cornerstone’s objective is to advance exploration / development stage copper and precious metals properties to production in the Americas. The Company’s Management and Board Core Competence is in exploration, permitting, development, construction, and operation of mining projects.

Cornerstone owns 100% (subject to 1.5% NSR) of the West Jerome property, near Jerome, Arizona, on the west side of Freeport McMoRan patented lands. The property, in a Volcanogenic Massive Sulfide camp, is a high-grade, massive sulfide target located 2.4 km south of the past-producing United Verde (32 million tons grading 4.4% copper, 1.5 oz/t silver and 0.04 oz/t gold). The West Jerome property has attractive untested drill targets.

ON BEHALF OF CORNERSTONE METALS INC.

per:

“Paul Cowley“
CEO & President

For further information, please contact:

Paul Cowley
Tel: 604-340-7711
Email: pcowley@cornerstonemetals.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Paul S. Cowley, P.Geo., President, CEO and director of the Company, is the Qualified Person as defined in NI43-101, who has reviewed and approved the technical content of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. There can be no assurance that any forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Cornerstone does not intend to revise or update these forward-looking statements after the date hereof or to revise them to reflect the occurrence of future unanticipated events.

SOURCE: Cornerstone Metals Inc.

ReleaseID: 439333

VANCOUVER, BC and MONTREAL, QC / ACCESSWIRE / April 28, 2016 / Lomiko Metals Inc. (“Lomiko”) (TSXV: LMR) (OTC: LMRMF) (FSE: DH8B) and Critical Elements Corporation (“Critical Elements” or the “Company”) (TSXV: CRE) (OTCQX: CRECF) (FSE: F12) are pleased to announce that Critical Elements and Lomiko have entered into an option agreement (“Agreement”) that gives Lomiko the right to acquire up to a 70% interest in the Bourier project.

“Recent consumer interest in electric vehicles has increased investor interest in Lithium and Graphite, two of the major components of a lithium-ion battery,” stated A. Paul Gill, CEO, “We are on the verge of reducing oil consumption and a creating a green economy. Quebec is in a unique positon of having ample supply of both commodities and is the focus of Lomiko’s mineral interests.”

“This option agreement with Lomiko will allow the Bourier property to be explored in detail for a Lithium Pegmatite discovery. Critical Elements is currently focused on the development of its Rose lithium project. With Lomiko farming into the Bourier project, shareholders of both companies will be able to benefit from successful exploration of a highly prospective project,” stated Jean-Sébastien Lavallée, President and CEO, Critical Elements.

The Bourier project consists of 228 claims for a total ground position of 11,579.28 hectares (116 km²) in a region of Quebec that boasts other lithium deposits and known lithium mineralization, as shown in the maps and table below. The Bourier project is potentially a new lithium field in an established lithium district.

Figure 1. Location of known lithium deposits and showing and Bourier Showing in the James Bay area of Quebec.

To view an enhanced version of Figure 1, please visit:
https://www.accesswire.com/uploads/20316_lomiko2.jpg

TERMS OF THE TRANSACTION

Under the Agreement, Lomiko will earn its interest in Bourier by way of a farm-in arrangement. The key terms of the Agreement are detailed in the below:

GRANT OF FIRST OPTION

Critical Elements grants to Lomiko the exclusive right and option to acquire, on or before December 31, 2017, an initial 49% Earned Interest in the Property Bourier by issuing to Critical Elements an aggregate of 5,000,000 common shares of Lomiko, by paying to Critical Elements $10,000 cash and by incurring or funding Exploration Expenditures for a total amount of $750,000 on the Property, as follows:

• paying to Critical Elements $10,000 cash within a delay of fifteen (15) days following the execution of this Agreement (non-refundable);
• issuing to Critical Elements 2,500,000 common shares immediately following the receipt of the required approvals from the Exchange, and issuing and additional 2,500,000 common shares on or before December 31, 2016; and
• incurring or funding Exploration Expenditures aggregating not less than $750,000 on the Property, of which an amount of $350,000 must be incurred or funded before December 31, 2016 and an amount of $400,000 before December 31, 2017.

GRANT OF SECOND OPTION

Subject to Lomiko having exercised the First Option, Critical Elements will also grant to Lomiko the exclusive right and option to increase its undivided interest in and to the Bourier Property from 49% to 70% by paying to Critical Elements an additional amount of $250,000, by incurring or funding additional Exploration Expenditures for an amount of $1,250,000 and by delivering a resource prepared in compliance with NI 43-101 standards on the Property prepared by a Qualified Person independent of Lomiko and Critical Elements, for a period commencing on the delivery of the First Option Exercise Notice and ending December 31, 2018, as follows:

• paying to Critical Elements an amount of $250,000, in cash or in common shares of Lomiko at the sole discretion of Lomiko, on or before the date of delivery of the First Option Exercise Notice;
• incurring or funding additional Exploration Expenditures for an amount of $1,250,000 on or before December 31, 2018; and
• delivering the Resource Estimate to Critical Elements on or before December 31, 2018.

MILESTONE PAYMENTS

Subject to Lomiko’s right to withdraw from and terminate the First Option, Lomiko agrees to pay the following milestones payments to Critical Elements, payable at any time following the exercise of the First Option upon the occurrence of the following:

• On the estimation of a drilled defined resource (NI 43-101 compliant) of 5,000,000 tonnes at a cut-off grade of 0.6% Li2O (all categories) a payment of Cad $500,000, payable in cash or in common shares of Lomiko at the sole discretion of Lomiko;
• On the estimation of a drilled defined resource (NI 43-101 compliant) of 10,000,000 tonnes at a cut-off grade of 0.6% Li2O (all categories) a payment of Cad $750,000, payable in cash or in common shares of Lomiko at the sole discretion of Lomiko;
• On the estimation of a drilled defined resource (Ni 43-101 compliant) of 15,000,000 tonnes at a cut-off grade of 0.6% Li2O (all categories) a payment of Cad $1,000,000, payable in cash or in common shares of Lomiko at the sole discretion of Lomiko; and
• On the estimation of a drilled defined resource (NI 43-101 compliant) of 20,000,000 tonnes at a cut-off grade of 0.6% Li2O (all categories) a payment of Cad $1,500,000, payable in cash or in common shares of Lomiko at the sole discretion of Lomiko.

ROYALTY

Following the exercise of the First Option by Lomiko, and in addition to the amounts paid, common shares issued and Exploration Expenditures incurred or funded by Lomiko under the First Option and thereafter under the Second Option, as applicable, Critical Elements shall receive a royalty equal to 2% net smelter returns resulting from the extraction and production of any Minerals on the Property.

The Royalty including the right of Lomiko to purchase a portion thereof (1%).

OPERATOR

During the agreement, Critical Elements shall act as the operator and as such, shall be responsible for carrying out and administering the Exploration Expenditures on the Property, in accordance with a work programs approved by the Parties regarding the Property.

Table 1. Lithium resources of the James Bay area

The Bourier property is located within the Opinaca Subprovince. Metagraywacke, derived migmatite, and granite characterize this subprovince. Poly-deformed schists occur at the belt margins, whereas the interior portions are metamorphosed to amphibolite and granulite facies (Percival, 2007). Mineralization in the Opinaca subprovince includes rare-metal occurrences within peraluminous granites and associated pegmatites.

A Technical Report has been performed by InnovExplo in 2012 Technical Report on the Bourier Property (according to Regulation 43-101 and Form 43-101F1) for Monarques Resources.

The area is characterized by metasedimentary rocks, mainly biotite paragneiss containing minerals typical of regional amphibolite metamorphic facies, and amphibole–plagioclase gneisses (amphibolites) of olcanic origin (Valiquette,1975). The northern boundary of the property is marked by intrusive pink granite. The metasedimentary rocks in the centre of the property are intruded by mafic and ultramafic rocks, granites, pegmatites, and late diabase dykes, the youngest rocks of the area. The amphibolites contain numerous lenses of ultramafic tremolite schist that follow the foliation of these amphibolites.

The biotite paragneiss crops out mainly in the low-lying ground. The paragneiss incorporates sills of mafic rock (amphibolites) and ultramafic rocks, metavolcanic layers, granite stocks and dykes, and pegmatite masses. These rocks dip on average 35° to the southwest (Valiquette 1975). The ultramafic rock in outcrop is mainly serpentinite, although narrow sills of ultramafic amphibole rocks are also present. These rocks may be crosscut by pegmatite dykes. Several granite intrusions cut the metasedimentary rocks. In some areas the granite intrudes the biotite gneisses. This granite is usually massive with very weak gneissic texture. The pegmatite dykes or sills cross-cut all the other rocks with the exception of the diabase. The pegmatites occur as two (2) sorts: pink, associated with oligoclase gneisses and granite, and white, associated with metasedimentary rocks. White pegmatites are generally fine to coarse grained containing muscovite, almandine garnet, black tourmaline (schorl), magnetite and biotite. Muscovite grains can be up to a few centimetres in size. The pink pegmatite ranges from fine to a very coarse grained variety comprising very large microcline crystals reaching up to 30 cm long. Besides quartz, microcline and plagioclase, the pegmatites also contain magnetite as large crystals up to 15 cm in length. Accessory minerals are apatite and garnet with trace amounts of spodumene.

The property is adjacent to the North-East to the Lemarre Lithium property option by Critical Elements to Lepidico in February 2016 (see press release dated February 11, 2016).

Lemare Property:

In October 2012, Monarques collected 43 channel samples from six trenches totalling 62 metres in length across the exposed spodumene pegmatite. Of these, 11 samples returned a Li₂O content superior to 2%. The results of the channel sampling are shown in the table below:

Table 2. Channel sampling results from Lemare (Monarques Resources Inc.)

Initial exploration at Lemare was undertaken in 2012 by Monarques Resources Inc. who discovered a “granite pegmatite dyke containing a considerable amount of spodumene.” The pegmatite ranges in apparent thickness from 4.8 to 14.2 metres and was followed for close to 200 metres in length on surface. The full length of the dyke remains unknown and is open in both directions. The pegmatite is undrilled so the depth extent also remains unknown.

Outside of work program complete between 2010 and 2012 for Zinc-Copper and Gold by Resource Monarque, there has been no lithium exploration undertaken at Bourier Property. Based on other lithium deposits around the world, it is a common occurrence for pegmatites to exist in “swarms.”Initial compilation of historical geological map and historical work already confirm the presence of pegmatite dyke and presence of spodumene and rare metals indicator. No value has been assigned to date in the compilation work as it is preliminary work.

Jean-Sébastien Lavallée (OGQ #773), geologist, shareholder of both companies, the President and Chief Executive Officer of the Critical Elements and a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.

For more information on Lomiko, review the website at www.lomiko.com, contact A. Paul Gill at 604-729-5312 or email: info@lomiko.com

On Behalf of the Board

“A. Paul Gill”
Chief Executive Officer

We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Lomiko Metals Inc.

ReleaseID: 439331

BOCA RATON, FL / ACCESSWIRE / April 28, 2016 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three months ended March 31, 2016.

Vycor’s revenues for the quarter were $400,000 compared to $329,000 for the same period in 2015, with revenues for the Vycor division up 35% and new patient starts in NovaVision up 38% over the same period in 2015. Cash burn(1) was $197,000, compared to $438,000 for the same period in 2015, a significant reduction of 55%, and non-GAAP net loss was $213,000, as compared to $473,000 in the prior year period.

Highlights

ViewSite Brain Access System (VBAS)

– Vycor’s VBAS sales grew by 35% in the first quarter compared to the first quarter of 2015, and by 56% compared to the fourth quarter of 2015, with growth being experienced in both the US and international markets. The significant body of clinical data now built up evidencing the clinical superiority of VBAS, with 7 papers being published or presented during 2015 alone, is now starting to flow through to increased adoption and revenues. Vycor is also benefitting from the ongoing restructuring and strengthening of its distribution network, with 17 sales reps being added since Q3 2015.

– In March 2016 Vycor launched its VBASMini, two new smaller models of its TC range. The VBASMini is the largest clear device available that can fit through a burr hole yet still provide a large enough working channel to be useful in neurosurgery, and was designed to overcome the limitations of carrying out work through the likes of an endoscopic sheath. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles.

– Vycor continues to build on its patent portfolio and has filed an additional three new patents for VBAS-related technologies during the first quarter of 2015.

NovaVision

– NovaVision provides computer-based therapies for home and clinic use for those with visual disorders as a result of stroke or other brain injury. Every 40 seconds someone suffers a stroke in the US, and up to 30% of these experience a resultant visual disorder. This is therefore a significant market, with a potential of $4 billion in the US and EU alone. NovaVision’s VRT is the only commercially available, FDA cleared therapy for the treatment of cerebral vision loss and is provided in a therapy suite with our complementary NeuroEyeCoach vision compensation program.

– NovaVision has four routes-to-market aimed at patients and professionals, comprising: direct-to-patient; rehabilitation centers and clinics; stroke associations and support groups; and physicians. Given the company’s limited resources, and the fact that historically over 50% of patients came through the Internet, NovaVision is initially focusing on its new website, www.novavision.com, as the core of a lead-driven inbound and outbound marketing strategy directed at prospective patients and relatives. Following the launch of the Internet-delivered therapy suite in Europe in December 2015, Novavision has rolled out this core direct-to-patient strategy with new websites in Germany www.novavision.de in January and the UK www.sightscience.com in March.

– NovaVision’s core development focus had been to reduce the cost of therapy delivery and make it more efficient and therefore scalable, and to broaden benefits with the new NeuroEyeCoach complementary compensation therapy. With the new Internet delivered therapy suite NovaVision has been able to achieve price reductions to patients of around 65%. It therefore takes time for increased patient volume to overtake the price reduction in revenue terms, but the increase in new patient starts in the first quarter of 73% in the US and 22% in Europe over the first quarter 2015 clearly demonstrates that patients and physicians are responding well to NovaVision’s new model. We now have approximately 190 patients currently undergoing NovaVision’s therapies.

– In early April we launched our NeuroEyeCoach Professional Center model in Germany which enables clinicians to treat patients with NeuroEyeCoach while they are in their care. Historically Germany has had a higher level of focus on the professional route-to-market and the response from clinics to the new product has been encouraging. A new NovaVision Professional Center model comprising both NeuroEyeCoach and VIDIT, the diagnostic component of VRT, will be launched to centers and clinics in the US within the next few weeks.

Management Commentary

“Vycor’s results for the first quarter of 2016 are a demonstration and realization of Vycor’s strategy to grow our two businesses while maintaining our low cost base, with the objective of continuing to decrease our Cash Burn(2),” said Peter Zachariou, CEO of Vycor Medical. “The Vycor division’s sales growth of 35% in the first quarter demonstrates the benefit of the clinical data flowing through to increased adoption, delivered by a distribution network in the process of being strengthened.”

“With the company’s limited resources we are focusing NovaVision initially on direct-to-patient website and social media marketing, before implementing the other marketing strategies. It takes an average of 10 weeks from contact to signing up a patient, and revenues are recognized over the therapy period, so the revenue benefits of the new model take time to build. The increase in new patient starts of 73% in the US and 22% in Europe in the first quarter over the first quarter in 2015 clearly demonstrates the market is responding to our strategy.”

“We have continued to reduce our Cash Burn(3), from $256,000 for the fourth quarter of 2015 to $197,000 for the first quarter of 2016 compared to $438,000 in the first quarter of 2015. We are focused on increasing revenues with the objective of continuing to decrease our Cash Burn.”

2016 Financial Results

Revenue totaled $400,000 in the first three months of 2016, as compared to $329,000 for the prior year, an increase of 22%. Vycor Medical’s revenue in the first three months of 2016 increased by $90,000 to $349,000, reflecting increased sales in the US and internationally. Gross margin was 82% for Vycor in versus 85% for the same period in 2015, mainly attributed to costs related to the migration to a new manufacturer and the manufacturing of the VBASMini.

NovaVision new patient starts in the US for the three months ended March 31, 2016 increased by 73% over the same period in 2015. The Internet-delivered therapy suite was launched in Europe in December 2015 and new patient starts in Europe for the three months ended March 31, 2016 increased by 22% over the same period in 2015.

Non-GAAP operating expenses in the first three months of 2016 totaled $534,000 as compared to $738,000 in the prior year period, a reduction of 28%.

Non-GAAP net operating loss in the first three months of 2016 was $201,000, as compared to $462,000 in the prior year period, a reduction of 56%.

Non-GAAP net loss in the first three months of 2016 was $213,000, as compared to $473,000 in the prior year period, a reduction of 55%.

Non-GAAP operating loss before depreciation and amortization (or “Cash Burn”) in the first three months of 2016 was $197,000, as compared to $438,000 in the prior year period.

Reconciliation of Non-GAAP Information

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash amortization of acquired intangible assets, non-cash stock-based compensation, and the change in value of derivative warrant liability. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

For the three months the Company reported Operating Expenses of $847,658 a net operating loss of $514,778 and a net loss of $527,564.

Vycor’s GAAP operating costs for the three months ended March 31, 2016 include non-cash amortization of acquired intangible assets ($58,617) and non-cash stock compensation charges ($254,763). Vycor’s other expenses were a loss on foreign currency exchange ($806).

The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

About Vycor Medical, Inc.

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

(1)non-GAAP operating loss before depreciation and amortization
(2)non-GAAP operating loss before depreciation and amortization
(3)non-GAAP operating loss before depreciation and amortization

Vycor Medical, Inc Contacts:

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc

ReleaseID: 439329

NEW YORK, NY / ACCESSWIRE / April 28, 2016 / The equities market is a survival game where you either come out a winner or you don’t. If you have yet to realize substantial returns on your chosen stocks, you might be doing something wrong and need ValuableInvestment.com to lead you in the right direction. Learn how you can earn big money today by subscribing for free at:

http://valuableinvestment.com/signup

In our continuous search for value, we have come across these four familiar names in the Internet Information Providers industry: Twitter Inc. (NYSE: TWTR), Yahoo! Inc. (NASDAQ: YHOO), Groupon Inc. (NASDAQ: GRPN), and JD.com Inc. (NASDAQ: JD). Get a head start on the market by joining our alert service at:

http://valuableinvestment.com/freealerts

Twitter Inc.’s shares recorded a trading volume of 84.64 million shares at the close on Wednesday, higher than their three months average volume of 22.40 million shares. The stock ended session at $14.86, which was a correction of 16.28%. The Company’s shares are trading below their 50-day moving average by 14.01%. Moreover, shares of Twitter have a Relative Strength Index (RSI) of 34.08. Do not lose out on any TWTR’s trade by activating your free access to the trade alerts now at:

http://valuableinvestment.com/TWTR

Shares in Yahoo! Inc. ended yesterday’s session at $36.95, which was a slight correction of 0.43%. A total volume of 16.39 million shares was traded. The stock has gained 1.73% in the past month, 24.45% in the previous three months, and 11.09% on an YTD basis. The Company’s shares are trading 7.18% above their 50-day moving average and 10.94% above their 200-day moving average. Moreover, Yahoo!’s stock has an RSI of 58.00. Sign up for your trade alert on YHOO at:

http://valuableinvestment.com/YHOO

On Wednesday, Groupon Inc.’s stock finished flat at $4.61 with a total volume of 13.58 million shares traded. The Company’s shares have advanced 16.12% in the last one month, 71.38% in the previous three months, and 50.16% on an YTD basis. The stock is trading 7.68% above its 50-day moving average and 23.51% above its 200-day moving average. Additionally, shares of Groupon have an RSI of 56.84. Register for free on ValuableInvestment.com and activate your trade alert on GRPN at:

http://valuableinvestment.com/GRPN

Shares in JD.com Inc. ended the day 1.08% higher at $25.34. A total volume of 22.13 million shares was traded, which was above their three months average volume of 12.20 million shares. The stock is trading below its 50-day moving average by 5.73%. Furthermore, shares of JD.com have an RSI of 36.72. Trade alert on JD is available for free at:

http://valuableinvestment.com/JD

—

About ValuableInvestment.com:

Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ValuableInvestment.com, the Author, the Reviewer, and the Sponsor (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our disclosures, or for more information, visit http://valuableinvestment.com/

RESTRICTIONS

ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press@valuableinvestment.com

SOURCE: ValuableInvestment.com

ReleaseID: 439324

NEW YORK, NY / ACCESSWIRE / April 28, 2016 / Leading equity crowdfunding platform, Crowdfunder, announced today that Steven McClurg is joining Crowdfunder as their President and Chief Operating Officer effective April 25, 2016. McClurg has built a strong reputation in the finance and tech industries during his more than 7-year career at Guggenheim Partners, a leading global investment and advisory financial services firm, most recently as managing director. In his role as President and Chief Operating Officer, McClurg will oversee all of the day-to-day operations of the Crowdfunder investment platform and will be responsible for growing the VC
Index Fund and greater investment practice.

While at Guggenheim Partners, McClurg was responsible for various areas of the investment management practice, including portfolio management and construction, overseeing private equity investments on behalf of Guggenheim’s largest institutional clients, product management and marketing, and emerging market and Eurobond debt analysis and trading. During his tenure, he helped Guggenheim Partners become one of the world’s foremost investment firms through their growth into the intermediary business, including launching and growing mutual funds and ETFs. Prior to Guggenheim, McClurg held various positions at Electronic Arts and Youbet.com including roles in strategic planning and financial analysis.

Chance Barnett, Founder and CEO of Crowdfunder, said, “We have worked with and known Steven for many years and I’m incredibly excited to bring someone with his level of deep institutional experience onto the Crowdfunder team.” Barnett continues, noting, “With the pivotal advances in the industry under the JOBS Act, and Crowdfunder’s unique Platform + VC Fund model, Steven has a track record for success and his experience in finance will be invaluable as our business evolves. This is the next step in the continued growth of the business as we look to scale out access for everyday investors to top tier VC-backed deal flow they would not otherwise see.”

“While my relationship with Chance Barnett and Crowdfunder initially attracted me to this opportunity,” said McClurg, “there is a huge potential to disrupt the financial industry with new regulation from the DOL and adoption of portions of the JOBS Act. I am passionate about helping entrepreneurs fund great ideas and being a part of the democratization of early-stage investing.”

About Crowdfunder

Crowdfunder is the equity crowdfunding leader for sourcing and funding high growth ventures with a network of over 130,000 entrepreneurs and investors. Crowdfunder and its VC Index Fund provide the opportunity for direct online investment into single ventures, as well as diversification into a broad VC-led portfolio (Index Fund) of early-stage startups – backed by many of the world’s leading Venture Capital firms and private investors. Get free access to private early-stage VC-backed startups on Crowdfunder.

Contact:

Meghan Holston
Coburn Communication, Inc.
Meghan.Holston@coburnww.com
212.730.7277

Caroline Brayson
Coburn Communication, Inc.
Caroline.Brayson@coburnww.com
212.730.7277

SOURCE: Crowdfunder, Inc.

ReleaseID: 439308

NEW YORK, NY / ACCESSWIRE / April 28, 2016 / From its origins as a military aid to mainstream use with regulatory approval and reimbursement, the exoskeleton, an electromechanical extention of legs and arms used for spinal cord trauma and stroke victims to restore mobility, is moving out of the physical therapy clinic into the world at large. This industry, swelling exponentiallty as populations age and more injury happens, has only a handful of players with varying degrees of technological savvy and forward-thinking leadership. Reflecting futuristic paradigms, companies like Cyberdyne (OTC: CYBQY), named after the supercomputer maker in Terminator, lead the way to revolutionary medicine.

The rehabilitation exoskeleton was pioneered by Ekso Bionics Holdings (OTCQB: EKSO), which posted $8.7 million in 2015 revenue. It also boasts recent FDA approval for its device to treat one-sided paralysis due to stroke (the first such approval in the US) and spinal cord damage covering most of the back and a portion of cervical vertebra – lending therapy to a large range of patients and expected to become standard of care in the clinic. The exoskeleton ‘suit’ comprises a backpack-like control center, sturdy leg, calf and hip support with embedded electronics, and a walking cane. EKSO’s customer base is wide and growing.

A relative newcomer to the exoskeleton scene, Bionik Laboratories (OTCQX: BNKL) built a sleeker version, ARKE, for rehabilitation and, eventually, home use. With design stemming from the work of two engineers delving into direct communication between brain and device, ARKE is more streamlined, lighter and more comfortable than Ekso’s product yet contains more sensors to detect and record movement. Also different, ARKE’s operation is wireless through a touch-controlled tablet with a longer battery life, and transmits data through an Internet cloud.

Bionik’s breadth of product offering is much bigger than Ekso. Whereas the latter caters to industries other than healthcare (factory workers and soldiers) to aid in lifting and carrying heavy loads, Bionik keeps laser-focused on its core competency: bringing patients closer to normal movement. In addition to ARKE, its unparalleled robotics technology is applied to arms, hands, wrists, ankles and knees, using proprietary intelligent interactive expertise that senses movement and limitations in a feedback loop to give the disabled help, as needed, in real-time. Offering even more value and credibility to its innovations, devices were designed and built in conjunction with MIT.

Also unique to Bionik is collaboration with IBM. Recognizing Bionik’s penchant for machine learning – an area the tech giant explores with MIT – IBM invited Bionik to join forces tapping how the human brain can be ‘computerized’ to aid in rehabilitative medicine. A plus for IBM: making headway into categorizing reams of human motion data used by clinicians; for Bionik: letting IBM and its privately-owned cloud organize patient information from ARKE, find patterns in sensory learning, and return to interested parties to improve outcomes in neurological rehabilitation.

Given the tight synergies among Bionik, IBM and MIT, it’s easy to understand Bionik’s acquisition of sister robotics firm Interaction Motion Technologies which gave Bionik a new line of products for both lower and upper body, commercialized in 20 countries. A ready-made revenue stream is now available while research and development ensues from the world’s best robotic minds, formerly of MIT and now part of Bionik Labs.

Bionik must not be grouped with the clutter of currently-available exoskeletons. Comparison with Ekso is likening a Jaguar to a Honda Civic. There is one competitor, however, suitable for association: Japanese based Cyberdyne, whose device has several of the same features as ARKE, most notably robotic aid to lower limbs rendered unworkable by neurological injury and use of bio-electric (nervous system) signals via feedback to effect limb movement. The similarity stops there. Bionik has a suite of devices to address many mobility maladies; Cyberdyne only one. Yet Cyberdyne trades at a market cap of $4.6 billion versus Bionik’s $78 million, an unwarranted discrepancy that, with deepening investor awareness of ARKE’s therapeutic value and vast product scope, should narrow considerably, and soon.

CONTACT:

Sharon di Stefano
SmallCapForecasting@gmail.com

SOURCE: Small Cap Forecasting, Inc.

ReleaseID: 439328

VANCOUVER, BC / ACCESSWIRE / April 28, 2016 / ALIX RESOURCES CORP. (“Alix” or the “Company”) (AIX-TSX:V) (37N.F–FRANKFURT) announces it has completed an initial sampling program at its Jackpot Lithium property (“Jackpot Property”) located in the Georgia Lake area within the Thunder Bay Mining Division, Ontario.

Approximately 90 kg of spodumene-bearing pegmatite rocks were collected from the surface and will be sent to the laboratory for assaying. At the request of Lithium Australia NL (“LIT”)(LIT-ASX) an additional 5-10 kg sample will be shipped to Australia for testing using LIT’s proprietary LIT’s proprietary Sileach™ process.

Lithium was first discovered in 1955 at the Jackpot property in granitic pegmatites. The property covers the Jackpot lithium deposits, described by E.G. Pye in a 1965 report published by the Ontario Depart. of Mines on the Georgia Lake Area. The deposits were tested by a total of 32 holes drilled in 1955 by Ontario Lithium Company Limited an its associated company Conwest Exploration Co. Ltd. The drilling confirmed the presence of at least two spodumene-bearing pegmatite bodies, one at the surface (No. 1) and the other (No. 2) lying directly beneath the No. 1 deposit. Historical resources at Jackpot, comprising only the No. 2 Dyke pegmatite zone, was reported as 2Mt @ 1.09 Li2O estimated in 1956 by Ontario Lithium Company Limited*. The No. 2 pegmatite dyke, which was discovered by diamond-drilling, was intersected at 30 to 100 meters intervals over a strike length of 215 meters and at 30-60 meters intervals over a distance of 365 meters across strike. Dyke No. 2 is 4 to 20 meters thick, averaging 11 meters.

*The estimates presented above are treated as historic information and have not been verified or relied upon for economic evaluation by the Company. These historical mineral resources do not refer to any category of sections 1.2 and 1.3 of the NI-43-101 Instrument such as mineral resources or mineral reserves as stated in the 2010 CIM Definition Standards on Mineral Resources and Mineral Reserves. The explanation lies in the inability by the Company to verify the data acquired by the various historical drilling campaigns. The Company has not done sufficient work yet to classify the historical estimates as current mineral resources or mineral reserves.

President and CEO Michael England commented, “We look forward to getting feedback from Lithium Australia with regards to samples collected from the Jackpot Lithium Project. We are also eager to commence work at our Electra Lithium Project in Mexico.”

Managing director Adrian Griffin of Lithium Australia NL states “Lithium chemical production, from spodumene, needs to be accomplished without roasting, to get into the lowest cost quartile. That’s what the Sileach™ process is all about. We will strive to give the Jackpot project the best possible process options, and that will start with Sileach™ evaluation.”

The technical contents of this release were approved by Michel Boily, PhD, P.Geo a Qualified Person as defined by National Instrument 43-101. The properties have not been the subject of a National Instrument 43-101 report.

Alix Resources is a junior mining exploration company focussed on seeking and acquiring world class lithium projects globally. Alix continues to evaluate suitable prospects that fit the mandate of the Company.

ON BEHALF OF THE BOARD

“Michael England”

Michael England, President, CEO, Director

FOR FURTHER INFORMATION, PLEASE CONTACT:

Telephone: 1-604-683-3995
Toll Free: 1-888-945-4770

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Alix Resources Corp.

ReleaseID: 439323